Caplin Point Laboratories Ltd - CAPLIN POINT LAB Share Price

Sector: Pharmaceuticals | ISIN: INE475E01026
₹ 1,303.35 (-0.44%) icon24 May, 2024, 12:00:00 AM

Caplin Point Laboratories Ltd KEY RATIOS

sector: Pharmaceuticals

  • CMP

    as on 5/24/2024 12:00:00 AM

    ₹ 1303.35 -5.80 -0.44
  • Open
  • ₹ 1,314.95
  • Prev. Close
  • ₹ 1,309.15
  • Turnover(Lac.)
  • ₹ 1,053
  • Day's High
  • ₹ 1,339
  • Day's Low
  • ₹ 1,299.05
  • 52 Week's High
  • ₹ 1,619.05
  • 52 Week's Low
  • ₹ 715.9
  • Book Value
  • ₹ 187.46
  • Face Value
  • ₹ 2
  • Mkt Cap (₹ Cr.)
  • 9,897.87
  • P/E
  • 34.86
  • EPS
  • 37.36
  • Divi. Yield
  • 0.19

Caplin Point Laboratories Ltd Corporate Actions

09 May , 2024

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

30 Jan , 2024

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

30 Jan , 2024

12:00 AM

01 Nov , 2023

12:00 AM

01 Nov , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

07 Aug , 2023

12:00 AM

AGM

Announcement date: 07 Aug , 2023

View Details

07 Aug , 2023

12:00 AM

Dividend

Dividend amount: 2.5
Announcement date: 07 Aug , 2023

View Details

31 Jul , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

31 Jul , 2023

12:00 AM

27 May , 2023

12:00 AM

Dividend

Dividend amount: 2
Announcement date: 27 May , 2023

View Details

13 May , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

08 Aug , 2023

12:00 AM

BookCloser

View Details

No Record Found


Caplin Point Laboratories Ltd News and Update

No Record Found

Invest wise with Expert advice

mobile icon
  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required

Caplin Point Laboratories Ltd SHAREHOLDING SNAPSHOT
24 May , 2024 | 07:44 PM

PROMOTER - TOTAL70.62%

Indian: 70.62%

Foreign: 0%

NON-PROMOTER - TOTAL 29.38%

Institutions: 4.42%

Non-Institutions: 24.95%

CUSTODIES - 0.00%

Custodies: 0.00%

See More Details
ad IconAd Image

Caplin Point Laboratories Ltd FINANCIALS

View Profit & Loss Graph

Caplin Point Laboratories Ltd PEER COMPARISON

Figures of Market Capital(Mar Cap), Quaterly Net Profit(NP Qtr) and Quaterly Sales(Sales Qtr) are in ₹ Cr.View All Peer Comparison

MORE ABOUT Caplin Point Laboratories Ltd

  • C C Paarthipan
  • Chairman & Non Executive Dir.
  • D Sathyanarayanan
  • Independent Non Exe. Director
  • C K Gariyali
  • Independent Director
  • Deenadayalan Singaram
  • Independent Non Exe. Director
  • R Nagendran
  • Independent Non Exe. Director
  • Sridhar Ganesan
  • Non Independent Executive Director / MD

Summary

Promoted by Mr. C. C. Paarthipan, Caplin Point Laboratories Limited was incorporated on April 16th, 1990. The Company is a fully integrated Pharma Company and is presently into the business of pharmaceuticals like producing, developing and marketing wide range of generic formulations and branded products and exporting to overseas market. Its main research and development facilities are located in Tamil Nadu, India and has a manufacturing plant in Puducherry, India. It has over 4000+ products registrations across the globe with over 650+ pharmaceutical formulations & over 36 therapeutic sections.Caplin markets a wide spectrum of pharmaceutical formulations and therapeutic segments in 23 countries. In addition to LATAM and Africa, it is now serving the US, European Union and other regulated markets as well. It manufactures products one among which is for injectables approved inter-alia by EU-GMP, INVIMA, Colombia, Anvisa, Brazil and US FDA. Besides these, it has extended to regulated markets like USA (plans for Canada, Australia, China and Brazil).The company came out with a public issue in Nov.94 and expanded its production capacity by setting up a new unit to manufacture its range of products, at Pondicherry. The company has retained its SSI status even after the expansion and thus will be out of the purview of the DPCO. During 1993-94, Triwin (a partnership firm) was merged with Caplin Point. The company entered into a technical agreement with American Remedies and Concord... Read More


Reports by Caplin Point Laboratories Ltd


Reports by Caplin Point Laboratories Ltd

Company FAQ

No Record Found